EHC
Encompass Health Corp
$104.01
+4.18%
$10.3B
No data for this timeframe.
Vol
Market Cap$10.3B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders9 funds
Inst. Value$1.6B
Inst. Activity2 buys / 1 sells
Insider Activity0B / 3S
Insider Net $-$4.3M
SEC Reports3
Recent Activity
Jun 1, 2026
SEC
Encompass Health issued $500 million of 5.875% Senior Notes due 2034 in a private offering, using the net proceeds (~$49
8-K — Impact 3/10
May 15, 2026
SEC
Encompass Health priced a $500M private offering of 5.875% senior notes due 2034, with net proceeds used to refinance hi
8-K — Impact 4/10
May 15, 2026
Insider
COLTHARP DOUGLAS E sold 27,694 shares
EVP & Chief Financial Officer @ $32.94 ($912.2K)
May 15, 2026
Insider
COLTHARP DOUGLAS E sold 27,693 shares
EVP & Chief Financial Officer @ $106.83 ($3.0M)
May 15, 2026
Insider
COLTHARP DOUGLAS E sold 27,694 shares
EVP & Chief Financial Officer @ $0.00 ($0.00)
Apr 30, 2026
SEC
Encompass Health reported Q1 2026 results with net operating revenue of $1.5866B (+9.0% YoY) and GAAP diluted EPS from c
8-K — Impact 7/10
Inst.
NORGES BANK — NEW
1,255,148 shares ($133.2M)
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
804,946 shares ($85.4M)
Price Targets
$140.50
+35.1% upside
Strong Buy
Current $104.01
Low $125.00
Median $140.00
High $152.00
12 analysts
$125.00
$152.00
Analyst Ratings
7Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | TD Cowen | INITIATE | Buy |
| May 5, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Feb 6, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Oct 30, 2025 | Barclays | MAINTAIN | Overweight → Overweight |
| Oct 2, 2025 | UBS | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $6.01 ▲ +1.5% | $5.74 — $6.12 | 10% YoY | 13 |
| Current Q | $1.48 | $1.42 — $1.52 | 6% YoY | 13 |
| Next Q | $1.36 ▼ -0.7% | $1.28 — $1.45 | 10% YoY | 13 |
| Next FY | $6.54 ▲ +0.9% | $6.15 — $6.71 | 9% YoY | 13 |
Latest Reports
NEUTRAL
8-K
3/10
Encompass Health issued $500 million of 5.875% Senior Notes due 2034 in a private offering, using the net proceeds (~$49
Jun 1, 2026
NEUTRAL
8-K
4/10
Encompass Health priced a $500M private offering of 5.875% senior notes due 2034, with net proceeds used to refinance hi
May 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.1B | — |
| NORGES BANK | $133.2M | NEW |
| BANK OF AMERICA CORP | $102.0M | — |
| MORGAN STANLEY | $97.5M | — |
| TWO SIGMA INVESTMENTS, LP | $85.4M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 15, 2026 | COLTHARP DOUGLAS | M | $912.2K |
| May 15, 2026 | COLTHARP DOUGLAS | SELL | $3.0M |
| May 15, 2026 | COLTHARP DOUGLAS | M | $0.00 |
| May 11, 2026 | Tuer Patrick | SELL | $71.3K |
| May 7, 2026 | Hayes Cain | A | $0.00 |
9 institutional holders with $1.6B total value (15,414,720 shares) as of 2025-Q4. Top holders: VANGUARD, NORGES, BANK. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 10,130,029 | $1.1B | 65.7% | — |
| 2 | NORGES BANK | 1,255,148 | $133.2M | 8.1% | NEW |
| 3 | BANK OF AMERICA CORP /DE/ | 961,184 | $102.0M | 6.2% | — |
| 4 | MORGAN STANLEY | 919,028 | $97.5M | 6.0% | — |
| 5 | TWO SIGMA INVESTMENTS, LP | 804,946 | $85.4M | 5.2% | ADD +59.2% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 680,399 | $72.2M | 4.4% | NEW |
| 7 | FMR LLC | 434,594 | $46.1M | 2.8% | TRIM -58.7% |
| 8 | WELLS FARGO & COMPANY/MN | 161,192 | $17.1M | 1.0% | — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 68,200 | $7.2M | 0.4% | ADD +35.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 1,255,148 | — | $133.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 505,641 | 804,946 | +59.2% | $85.4M | 2025-Q4 |
| FMR LLC | TRIM | 1,052,559 | 434,594 | -58.7% | $46.1M | 2025-Q4 |
| FMR LLC | TRIM | 1,698,970 | 1,052,559 | -38.0% | $133.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 52,400 | 71,000 | +35.5% | $9.0M | 2025-Q3 |
| NORGES BANK | EXIT | 1,137,860 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 1,137,860 | — | $139.5M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 170,306 | 504,012 | +195.9% | $61.8M | 2025-Q2 |
| UBS Group AG | TRIM | 281,965 | 129,694 | -54.0% | $15.9M | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 452,516 | 1,071,555 | +136.8% | $108.5M | 2025-Q1 |
| UBS Group AG | ADD | 207,703 | 281,965 | +35.8% | $28.6M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 302,317 | 170,306 | -43.7% | $17.2M | 2025-Q1 |
| NORGES BANK | EXIT | 1,089,733 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 804,355 | 452,516 | -43.7% | $41.8M | 2024-Q4 |
| UBS Group AG | DOUBLED | 84,716 | 207,703 | +145.2% | $19.2M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 31,200 | 50,900 | +63.1% | $4.7M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 640,419 | — | $61.9M | 2024-Q3 |
16 unique insiders with 3 transactions. Net insider value: -$4.3M ($0.00 bought, $4.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 15, 2026 | COLTHARP DOUGLAS E | EVP & Chief Financial Officer | M | 27,694 | $32.94 | $912.2K |
| May 15, 2026 | COLTHARP DOUGLAS E | EVP & Chief Financial Officer | SELL | 27,693 | $106.83 | $3.0M |
| May 15, 2026 | COLTHARP DOUGLAS E | EVP & Chief Financial Officer | M | 27,694 | $0.00 | $0.00 |
| May 11, 2026 | Tuer Patrick William | EVP, Chief Operating Officer | SELL | 682 | $104.56 | $71.3K |
| May 7, 2026 | Hayes Cain A | Director | A | 1,634 | $0.00 | $0.00 |
| May 7, 2026 | Reidy Christopher R | Director | A | 1,634 | $0.00 | $0.00 |
| May 7, 2026 | Christie Edward M III | Director | A | 1,634 | $0.00 | $0.00 |
| May 7, 2026 | O'Connor Kevin J. | Director | A | 1,634 | $0.00 | $0.00 |
| May 7, 2026 | SCHLICHTING NANCY M | Director | A | 1,634 | $0.00 | $0.00 |
| May 7, 2026 | KATZ LESLYE G | Director | A | 1,634 | $0.00 | $0.00 |
| May 7, 2026 | HERMAN JOAN E | Director | A | 1,634 | $0.00 | $0.00 |
| May 7, 2026 | Williams Terrance | Director | A | 1,634 | $0.00 | $0.00 |
| May 7, 2026 | CARMICHAEL GREG D | Director | A | 1,634 | $0.00 | $0.00 |
| Apr 16, 2026 | Christie Edward M III | Director | A | 261 | $106.17 | $27.7K |
| Apr 16, 2026 | Reidy Christopher R | Director | A | 334 | $106.48 | $35.6K |
| Apr 15, 2026 | CARMICHAEL GREG D | Director | A | 27 | $0.00 | $0.00 |
| Apr 15, 2026 | Williams Terrance | Director | A | 27 | $0.00 | $0.00 |
| Apr 15, 2026 | SCHLICHTING NANCY M | Director | A | 39 | $0.00 | $0.00 |
| Apr 15, 2026 | Reidy Christopher R | Director | A | 19 | $0.00 | $0.00 |
| Apr 15, 2026 | O'Connor Kevin J. | Director | A | 17 | $0.00 | $0.00 |
| Apr 15, 2026 | KATZ LESLYE G | Director | A | 85 | $0.00 | $0.00 |
| Apr 15, 2026 | HERMAN JOAN E | Director | A | 85 | $0.00 | $0.00 |
| Apr 15, 2026 | Hayes Cain A | Director | A | 1 | $0.00 | $0.00 |
| Apr 15, 2026 | Christie Edward M III | Director | A | 9 | $0.00 | $0.00 |
| Mar 9, 2026 | Fay Edmund | Sr. Vice Pres. and Treasurer | SELL | 11,937 | $107.00 | $1.3M |
| Mar 9, 2026 | Fay Edmund | Sr. Vice Pres. and Treasurer | G | 3,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Darby John Patrick | EVP, Gen Counsel & Secretary | A | 5,967 | $108.06 | $644.8K |
| Mar 2, 2026 | Tarr Mark J | President & CEO | A | 35,461 | $108.06 | $3.8M |
| Mar 2, 2026 | Tuer Patrick William | EVP, Chief Operating Officer | A | 10,502 | $108.06 | $1.1M |
| Mar 2, 2026 | COLTHARP DOUGLAS E | EVP & Chief Financial Officer | A | 12,275 | $108.06 | $1.3M |
| Feb 28, 2026 | Price Andrew L | Chief Accounting Officer | F | 307 | $107.88 | $33.1K |
| Feb 28, 2026 | Charbonneau Elissa Joy | Chief Medical Officer | F | 369 | $107.88 | $39.8K |
| Feb 28, 2026 | Fay Edmund | Sr. Vice Pres. and Treasurer | F | 280 | $107.88 | $30.2K |
| Feb 28, 2026 | Tarr Mark J | President & CEO | F | 2,187 | $107.88 | $235.9K |
| Feb 28, 2026 | Darby John Patrick | EVP, Gen Counsel & Secretary | F | 416 | $107.88 | $44.9K |
| Feb 28, 2026 | Tuer Patrick William | EVP, Chief Operating Officer | F | 545 | $107.88 | $58.8K |
| Feb 28, 2026 | COLTHARP DOUGLAS E | EVP & Chief Financial Officer | F | 776 | $107.88 | $83.7K |
| Feb 23, 2026 | Price Andrew L | Chief Accounting Officer | F | 404 | $106.15 | $42.9K |
| Feb 23, 2026 | Tuer Patrick William | EVP, Chief Operating Officer | F | 506 | $106.15 | $53.7K |
| Feb 23, 2026 | COLTHARP DOUGLAS E | EVP & Chief Financial Officer | F | 14,818 | $106.15 | $1.6M |
| Feb 23, 2026 | Tarr Mark J | President & CEO | F | 2,488 | $106.15 | $264.1K |
| Feb 23, 2026 | Fay Edmund | Sr. Vice Pres. and Treasurer | F | 380 | $106.15 | $40.3K |
| Feb 23, 2026 | Charbonneau Elissa Joy | Chief Medical Officer | F | 440 | $106.15 | $46.7K |
| Feb 23, 2026 | Darby John Patrick | EVP, Gen Counsel & Secretary | F | 6,990 | $106.15 | $742.0K |
| Feb 20, 2026 | Darby John Patrick | EVP, Gen Counsel & Secretary | F | 328 | $106.55 | $34.9K |
| Feb 20, 2026 | Tuer Patrick William | EVP, Chief Operating Officer | F | 405 | $106.55 | $43.2K |
| Feb 20, 2026 | Price Andrew L | Chief Accounting Officer | F | 228 | $106.55 | $24.3K |
| Feb 20, 2026 | COLTHARP DOUGLAS E | EVP & Chief Financial Officer | F | 674 | $106.55 | $71.8K |
| Feb 20, 2026 | Charbonneau Elissa Joy | Chief Medical Officer | F | 287 | $106.55 | $30.6K |
| Feb 20, 2026 | Tarr Mark J | President & CEO | F | 1,797 | $106.55 | $191.5K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
3/10
Encompass Health issued $500 million of 5.875% Senior Notes due 2034 in a private offering, using th
Jun 1, 2026
NEUTRAL
8-K
4/10
Encompass Health priced a $500M private offering of 5.875% senior notes due 2034, with net proceeds
May 15, 2026
BULLISH
8-K
7/10
Encompass Health reported Q1 2026 results with net operating revenue of $1.5866B (+9.0% YoY) and GAA
Apr 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 7 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$140.50 mean target
+35.1% upside
Strong Buy (1.08)
$125.00 Low
$152.00 High
| Metric | Value |
|---|---|
| Current Price | $104.01 |
| Target Low | $125.00 |
| Target Mean | $140.50 |
| Target Median | $140.00 |
| Target High | $152.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.08) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current FY 2026-12-31 |
$6.01 | $5.74 | $6.12 | 10.3% | +1.5% | 12↑ 0↓ | $6.4B | 8.2% | 13 |
| Current Q 2026-06-30 |
$1.48 | $1.42 | $1.52 | 5.7% | +0.1% | 5↑ 5↓ | $1.6B | 7.9% | 13 |
| Next Q 2026-09-30 |
$1.36 | $1.28 | $1.45 | 10.4% | -0.7% | 5↑ 6↓ | $1.6B | 7.9% | 13 |
| Next FY 2027-12-31 |
$6.54 | $6.15 | $6.71 | 8.8% | +0.9% | 9↑ 3↓ | $6.9B | 8.1% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.479 | |
| 7d ago | $1.483 | -0.004 |
| 30d ago | $1.477 | +0.002 |
| 60d ago | $1.483 | -0.004 |
| 90d ago | $1.486 | -0.007 |
12 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | TD Cowen | INITIATE | — | Buy |
| May 5, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 6, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Oct 30, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Oct 2, 2025 | UBS | MAINTAIN | Buy | Buy |
| Sep 16, 2025 | Keybanc | MAINTAIN | Overweight | Overweight |
| Sep 10, 2025 | B of A Securities | MAINTAIN | Buy | Buy |
| Aug 14, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
| Aug 6, 2025 | UBS | MAINTAIN | Buy | Buy |
| Jun 5, 2025 | Stephens & Co. | REITERATE | Overweight | Overweight |
| May 27, 2025 | Keybanc | MAINTAIN | Overweight | Overweight |
| Apr 28, 2025 | UBS | MAINTAIN | Buy | Buy |
| Apr 28, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 28, 2025 | Truist Securities | REITERATE | Buy | Buy |
| Apr 25, 2025 | Keybanc | MAINTAIN | Overweight | Overweight |
| Apr 25, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 11, 2025 | RBC Capital | REITERATE | Outperform | Outperform |
| Feb 10, 2025 | Keybanc | MAINTAIN | Overweight | Overweight |
| Feb 7, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Oct 30, 2024 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Oct 30, 2024 | Truist Securities | REITERATE | Buy | Buy |
| Oct 29, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Oct 29, 2024 | Keybanc | MAINTAIN | Overweight | Overweight |
| Oct 14, 2024 | Truist Securities | MAINTAIN | Buy | Buy |
| Oct 11, 2024 | Keybanc | INITIATE | — | Overweight |
| Sep 26, 2024 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Sep 25, 2024 | UBS | MAINTAIN | Buy | Buy |
| Aug 15, 2024 | Truist Securities | MAINTAIN | Buy | Buy |
| Aug 8, 2024 | UBS | MAINTAIN | Buy | Buy |
| Aug 6, 2024 | Stephens & Co. | REITERATE | Overweight | Overweight |
| Aug 6, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Jul 15, 2024 | Truist Securities | MAINTAIN | Buy | Buy |
| Jul 10, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Jul 10, 2024 | Leerink Partners | INITIATE | — | Outperform |
| Jun 5, 2024 | Stephens & Co. | REITERATE | Overweight | Overweight |
| May 22, 2024 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 26, 2024 | Raymond James | REITERATE | Strong Buy | Strong Buy |
| Apr 25, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 25, 2024 | Mizuho | MAINTAIN | Buy | Buy |
| Mar 28, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 6, 2024 | Barclays | INITIATE | — | Overweight |
| Feb 9, 2024 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 9, 2024 | RBC Capital | REITERATE | Outperform | Outperform |
| Feb 9, 2024 | Mizuho | MAINTAIN | Buy | Buy |
| Jan 16, 2024 | Stephens & Co. | REITERATE | Overweight | Overweight |
| Sep 28, 2023 | RBC Capital | REITERATE | Outperform | Outperform |
| Aug 8, 2023 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Aug 4, 2023 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Aug 4, 2023 | Credit Suisse | MAINTAIN | Outperform | Outperform |
| Aug 3, 2023 | Raymond James | MAINTAIN | Strong Buy | Strong Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 11, 2026
dark_pool
Dark Pool: EHC — 1.3M shares, 34,214 trades
Week starting 2026-05-11. Total ATS volume: 1,278,901 shares across 34,214 trades.
May 4, 2026
dark_pool
Dark Pool: EHC — 1.7M shares, 38,629 trades
Week starting 2026-05-04. Total ATS volume: 1,680,007 shares across 38,629 trades.
May 1, 2026
short_volume
Short Volume: EHC — 61.0% short (0.5M / 0.7M)
Short: 455,907 | Exempt: 100 | TRF Vol: 747,396 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_interest
FTD: EHC — 8,713 shares ($0.9M) failed to deliver
Settlement: 20260501, Price: $100.00, FTD Value: $871,300, ENCOMPASS HEALTH CORP COM (DE)
Apr 30, 2026
short_volume
Short Volume: EHC — 56.2% short (0.4M / 0.7M)
Short: 416,168 | Exempt: 0 | TRF Vol: 740,332 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings_calendar
EHC Q1 2026 Earnings After Market Close — 2026-04-30
Apr 29, 2026
short_volume
Short Volume: EHC — 56.3% short (0.3M / 0.6M)
Short: 316,400 | Exempt: 336 | TRF Vol: 561,620 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
dark_pool
Dark Pool: EHC — 2.2M shares, 45,843 trades
Week starting 2026-04-27. Total ATS volume: 2,216,115 shares across 45,843 trades.
Apr 20, 2026
dark_pool
Dark Pool: EHC — 1.1M shares, 27,962 trades
Week starting 2026-04-20. Total ATS volume: 1,089,221 shares across 27,962 trades.
Apr 13, 2026
dark_pool
Dark Pool: EHC — 1.3M shares, 33,574 trades
Week starting 2026-04-13. Total ATS volume: 1,264,561 shares across 33,574 trades.
Apr 6, 2026
dark_pool
Dark Pool: EHC — 1.7M shares, 40,286 trades
Week starting 2026-04-06. Total ATS volume: 1,707,688 shares across 40,286 trades.
Apr 6, 2026
short_volume
Short Volume: EHC — 68.5% short (0.4M / 0.6M)
Short: 440,193 | Exempt: 1,916 | TRF Vol: 642,388 | Short Ratio: 68.5% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
dark_pool
Dark Pool: EHC — 0.9M shares, 25,503 trades
Week starting 2026-03-30. Total ATS volume: 923,000 shares across 25,503 trades.
Mar 23, 2026
dark_pool
Dark Pool: EHC — 1.0M shares, 28,726 trades
Week starting 2026-03-23. Total ATS volume: 1,037,050 shares across 28,726 trades.
Mar 16, 2026
dark_pool
Dark Pool: EHC — 1.1M shares, 29,187 trades
Week starting 2026-03-16. Total ATS volume: 1,149,890 shares across 29,187 trades.